Metformin attenuates hypoxia-induced resistance to cisplatin in the HepG2 cell line.
In conclusion, a low concentration of metformin attenuates hypoxia-induced resistance to cisplatin in HepG2 cells. Selective delivery of an effective dose of metformin to a hepatoblastoma tumor may be achievable and clinically useful with TACE.
PMID: 30719114 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Children | Diabetes | Diabetes Type 2 | Endocrinology | Environmental Health | Fortamet | Hepatoblastoma | Liver | Metformin | Study | Urology & Nephrology